Every article, report, and earnings note where RMD appears.
ResMed Inc. (RMD) falls after hours as investors react to a softer fiscal 2027 outlook tied to suspended ventilator sales and higher cost pressure. The company still topped Q4 EPS estimates and posted solid full-year revenue growth, but guidance concerns are driving the selloff.
The $490 million MatrixCare sale and planned ASR improve capital-return optics, but they do not answer the FY2027 growth question. With a 60/100 Growth component in the TickerSpark Score and a 20.30 P/E, RMD remains a defensive setup before the next proof point.
ResMed pairs double-digit revenue growth, strong margins, and net cash with a large underpenetrated sleep-apnea market. The stock remains a Buy, but valuation and an Astral field-action headwind temper upside.
ResMed Inc. (RMD) falls sharply after its fiscal Q4 earnings release, even as revenue hit a record and EPS rose. Investors are weighing strong sales growth against softer operating margin and weaker free cash flow, which raised questions about whether the stock’s prior valuation was too rich.
Apnimed, Inc. (NASDAQ: APMD) is expected to list on 2026-07-31 in a $14.00 to $16.00 range, offering 10,000,000 shares. The setup is compelling if investors want a late-stage sleep-apnea catalyst, but the deal still hinges on FDA approval and commercial execution.
Intuitive Surgical trades at a premium because it is still delivering premium operating results. With procedure growth running around 17%, revenue up 20.5%, and the da Vinci installed base still expanding double digits, the usual "too expensive" knock misses what the business is actually doing.
Generate an AI-powered research report — grades, price targets, financials, and chart analysis on demand.
Generate RMD ReportCancel anytime